Barinthus Biotherapeutics CEO Change & Director Departure
Ticker: BRNS · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1828185
| Field | Detail |
|---|---|
| Company | Barinthus Biotherapeutics PLC. (BRNS) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, director-departure, ceo-appointment
TL;DR
CEO change at Barinthus, Howell takes the helm, Jonathan out.
AI Summary
Barinthus Biotherapeutics plc announced on November 25, 2024, the departure of Director Jonathan Jonathan and the appointment of Dr. Sarah Howell as Chief Executive Officer. The company also reported on compensatory arrangements for certain officers.
Why It Matters
A change in CEO can significantly impact a company's strategic direction and investor confidence. The departure of a director also signals potential shifts within the board.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the CEO level, introduce uncertainty and potential strategic shifts that can affect the company's performance.
Key Players & Entities
- Barinthus Biotherapeutics plc (company) — Registrant
- Jonathan Jonathan (person) — Departing Director
- Sarah Howell (person) — Appointed Chief Executive Officer
FAQ
Who has been appointed as the new Chief Executive Officer of Barinthus Biotherapeutics plc?
Dr. Sarah Howell has been appointed as the new Chief Executive Officer.
Who is the departing director from Barinthus Biotherapeutics plc?
Jonathan Jonathan is the departing director.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is November 25, 2024.
What is the former name of Barinthus Biotherapeutics plc?
The company was formerly known as Vaccitech plc and Vaccitech Ltd.
What is the Standard Industrial Classification code for Barinthus Biotherapeutics plc?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-11-25 16:06:18
Filing Documents
- brns-20241125.htm (8-K) — 27KB
- brns-20241125xexx991.htm (EX-99.1) — 13KB
- a1.jpg (GRAPHIC) — 5KB
- 0001828185-24-000093.txt ( ) — 224KB
- brns-20241125.xsd (EX-101.SCH) — 3KB
- brns-20241125_def.xml (EX-101.DEF) — 17KB
- brns-20241125_lab.xml (EX-101.LAB) — 29KB
- brns-20241125_pre.xml (EX-101.PRE) — 17KB
- brns-20241125_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On November 25, 2024, the Company issued a press release titled "Barinthus Bio Promotes SNAP-TI Co-Inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer." The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated November 2 5 , 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Barinthus Biotherapeutics plc Date: November 25, 2024 By: /s/ William Enright William Enright Chief Executive Officer